Gene Therapy (Onasemnogene Abeparvovec) Is Safe and Effective in Children with Spinal Muscular Atrophy Type 1 on Invasive Long-Term Ventilation

被引：0
|
作者：
Narayan, O. [1 ]
Alajjuri, M. [2 ]
Abusamra, R. [3 ]
Mundada, V [4 ]
机构：
[1] Amer Hosp Dubai, Pediat Pulmonol, Dubai, U Arab Emirates
[2] Univ Sharjah, Sharjah, U Arab Emirates
[3] Mediclin Hosp Dubai, Pediat Pulmonol, Dubai, U Arab Emirates
[4] Medcare Hosp Dubai, Pediat Neurol, Dubai, U Arab Emirates
来源：
PEDIATRIC PULMONOLOGY | 2023年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
H 139
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [31] Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial
    Mendell, Jerry R.
    Shell, Richard
    Lehman, Kelly J.
    McColly, Markus
    Lowes, Linda P.
    Alfano, Lindsay N.
    Miller, Natalie F.
    Iammarino, Megan A.
    Church, Kathleen
    Ogrinc, Francis G.
    Ouyang, Haojun
    Kernbauer, Elaine
    Joshi, Shivani
    Sproule, Douglas M.
    Meriggioli, Matthew
    Feltner, Douglas E.
    Al-Zaidy, Samiah
    NEUROLOGY, 2020, 94 (15)
  • [32] Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy
    Lee, Seungbok
    Lee, Yun Jeong
    Kong, Juhyun
    Ryu, Hye Won
    Shim, Young Kyu
    Han, Ji Yeon
    Woo, Hyewon
    Kim, Soo Yeon
    Cho, Anna
    Lim, Byung Chan
    Chae, Jong Hee
    BRAIN & DEVELOPMENT, 2022, 44 (04): : 287 - 293
  • [33] Gene therapy for spinal muscular atrophy with onasemnogene abeparvovec. Statement of the German Speaking Society of Neuropediatrics
    Kirschner, Janbernd
    Bernert, Guenther
    v der Hagen, Maja
    Hahn, Andreas
    Johannsen, Jessika
    Klein, Andrea
    Mueller-Felber, Wolfgang
    Ziegler, Andreas
    Schara, Ulrike
    MONATSSCHRIFT KINDERHEILKUNDE, 2020, 168 (10) : 938 - 941
  • [34] Value of onasemnogene abeparvovec in spinal muscular atrophy type 1: improvements in motor function, ventilation-free survival, and hospitalizations
    Dabbous, O.
    Reyna, S.
    Feltner, D.
    Ogrinc, F.
    Menier, M.
    Ouyang, H.
    Droege, M.
    Bischof, M.
    LaMarca, N.
    Arunji, R.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S123 - S123
  • [35] Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update
    Strauss, K.
    Farrar, M.
    Swoboda, K.
    Saito, K.
    Chiriboga, C.
    Finkel, R.
    Iannaccone, S.
    Krueger, J.
    Kwon, J.
    McMillan, H.
    Servais, L.
    Mendell, J.
    Parsons, J.
    Scoto, M.
    Shieh, P.
    Zaidman, C.
    Schultz, M.
    Ogrinc, F.
    Group, S.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S122 - S122
  • [36] Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates
    Mundada, Vivek
    Narayan, Omendra
    Arora, Siddharth
    Beri, Nidhi
    Abusamra, Rania
    Mullasery, Deepak
    Parashar, Deepak
    MUSCLE & NERVE, 2024, 70 (04) : 808 - 815
  • [37] Real-world experience of delivering gene-therapy with onasemnogene abeparvovec (Zolgensma®) for children with spinal muscular atrophy (SMA) type-1 in the UK
    Gowda, V
    Jungbluth, H.
    Standing, E.
    Sheehan, J.
    Hughes, I
    Mccullagh, G.
    Atherton, M.
    Ong, M.
    Majumdar, A.
    Murugan, A.
    Dhawan, A.
    Muntoni, F.
    Baranello, G.
    Scoto, M.
    Manzur, A.
    Munot, P.
    Abbot, L.
    Horrocks, I
    Tirupathi, S.
    Wraige, E.
    NEUROMUSCULAR DISORDERS, 2022, 32
  • [38] Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec
    Beri, Nidhi
    Kapoor, Lekha
    Parashar, Deepak
    Mundada, Vivek
    ARCHIVES OF DISEASE IN CHILDHOOD, 2023, 108 (10) : 866 - 867
  • [39] Long-term safety of onasemnogene abeparvovec for patients with spinal muscular atrophy: real-world findings from the RESTORE Registry
    Servais, L.
    Alecu, I.
    Lopez-Leon, S.
    Ilic, A.
    Brueckner, A.
    Benguerba, K.
    Reyna, S.
    Dabbous, O.
    Mumneh, N.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [40] Onasemnogene abeparvovec AAV vector-based gene-replacement therapy Treatment of spinal muscular atrophy
    Paton, D. M.
    DRUGS OF THE FUTURE, 2019, 44 (08) : 625 - 633
12345